MASH is diagnosed by biopsy, which makes its trials small, slow and unusually clear-cut: you either see the tissue change or you do not. The sequence below starts with 52 people on liraglutide in 2016, moves through the dose-finding work that made semaglutide look promising, and arrives at two readouts that matter commercially as well as clinically, tirzepatide's phase 2 and semaglutide's phase 3. Alongside them, survodutide, retatrutide and pemvidutide are each testing, in different combinations, a separate bet that adding glucagon agonism to a GLP-1 burns liver fat faster. One trial here failed, and it is the most informative on the list.
Ranked papers
#1SYNERGY-NASH
Loomba R, Hartman ML, Lawitz EJ, et al. · N Engl J Med · 2024
What it measured: Liver inflammation resolved on biopsy at one year, with scarring no worse
190 patients with biopsy-proven MASH at stage F2 or F3, given one of three doses or a placebo over 52 weeks. Resolution without fibrosis worsening reached 44%, 56% and 62% against 10% on placebo. It is the strongest randomized dataset for a dual agonist in this disease and the basis of the phase 3 program now running. It is still phase 2, and 52 weeks is short for a disease measured in decades.
PMID 38856224 ↗NCT04166773 ↗DOI 10.1056/NEJMoa2401943 ↗
#2ESSENCE
Sanyal AJ, Newsome PN, Kliers I, et al. · N Engl J Med · 2025
What it measured: Two biopsy measures at 72 weeks: inflammation resolving, and scarring improving
The phase 3 result, in 800 biopsy-confirmed patients with F2 or F3 fibrosis. At 72 weeks, 62.9% on semaglutide had resolution without fibrosis worsening against 34.3% on placebo, and 36.8% showed fibrosis improvement against 22.4%. Weight fell 10.5% against 2.0%. Note how high the placebo numbers are. A third of untreated patients improved, which is characteristic of biopsy endpoints and a reason to read single-arm claims in this field skeptically. It has since led to Wegovy's accelerated approval for MASH with F2 to F3 fibrosis.
PMID 40305708 ↗NCT04822181 ↗DOI 10.1056/NEJMoa2413258 ↗
#3
Newsome PN, Buchholtz K, Cusi K, et al. · N Engl J Med · 2021
What it measured: Liver inflammation resolved on biopsy at 72 weeks, with scarring no worse
The dose-finding trial that made the phase 3 program possible: 320 patients with biopsy-confirmed disease across three daily doses for 72 weeks, with resolution reaching 59% at the top dose against 17%. But it missed its fibrosis endpoint. The drug cleared the inflammation without demonstrably reversing the scarring. ESSENCE later closed that gap with the once-weekly 2.4 mg dose, and the gap is why the distinction between resolution and fibrosis improvement is worth keeping straight.
PMID 33185364 ↗NCT02970942 ↗DOI 10.1056/NEJMoa2028395 ↗
#4Survodutide phase 2
Sanyal AJ, Bedossa P, Fraessdorf M, et al. · N Engl J Med · 2024
What it measured: A meaningful drop in the liver-inflammation score at 48 weeks, without more scarring
293 patients on survodutide, which combines glucagon agonism with GLP-1, at three doses for 48 weeks. Improvement without fibrosis worsening hit 47%, 62% and 43% against 14%, and a fibrosis gain of one stage or more was seen in 34%, 36% and 34% against 22%. Note the non-monotonic pattern: the highest dose did worse than the middle one. The dip is a real feature of these data, not rounding, and a caution against assuming more is better.
PMID 38847460 ↗NCT04771273 ↗DOI 10.1056/NEJMoa2401755 ↗
#5Retatrutide MASLD phase 2a
Sanyal AJ, Kaplan LM, Frias JP, et al. · Nat Med · 2024
What it measured: How much liver fat disappeared on MRI over 24 weeks
A liver sub-study of retatrutide's obesity trial: 98 adults with at least 10% liver fat on imaging. Across four doses, liver fat fell 51%, 59%, 82% and 86% at 48 weeks against about 5% on placebo, with 89% and 93% of the two highest-dose groups dropping below the 5% threshold that defines a normal liver. Weight fell up to 26%. This was measured by scan, not biopsy, so it shows fat clearing, not proof that inflammation or scarring resolved.
PMID 38858523 ↗NCT04881760 ↗DOI 10.1038/s41591-024-03018-2 ↗
#6LEAN
Armstrong MJ, Gaunt P, Aithal GP, et al. · Lancet · 2016
What it measured: Liver inflammation resolved on biopsy at 48 weeks, with scarring no worse
Where it began: 52 overweight adults with biopsy-confirmed disease, randomized to liraglutide or placebo for 48 weeks. Resolution occurred in 39% against 9%. The confidence interval ran from 1.0 to 17.7, which is another way of saying 52 people is not many. It was never meant to settle anything; it was the proof of concept that justified every larger trial on this list.
PMID 26608256 ↗NCT01237119 ↗DOI 10.1016/S0140-6736(15)00803-X ↗
#7Semaglutide MASH-cirrhosis phase 2
Loomba R, Abdelmalek MF, Armstrong MJ, et al. · Lancet Gastroenterol Hepatol · 2023
What it measured: Liver scarring improving by at least one stage on biopsy, in cirrhosis
The most useful failure in this field. It put 71 patients with cirrhosis from MASH, the advanced end of the disease, on semaglutide or placebo for 48 weeks. The fibrosis endpoint was missed, and the numbers even ran backwards: 11% improved on the drug against 29% on placebo. Resolution nominally favored semaglutide but did not reach significance. Once scarring reaches cirrhosis, the evidence that these drugs help is absent, and the positive results on this list all come from earlier-stage disease.
PMID 36934740 ↗NCT03987451 ↗DOI 10.1016/S2468-1253(23)00068-7 ↗
#8IMPACT
Noureddin M, Harrison SA, Loomba R, et al. · Lancet · 2025
What it measured: Inflammation resolving and scarring improving on biopsy, after only 24 weeks
212 patients on pemvidutide, another GLP-1 and glucagon combination, for just 24 weeks, with resolution at 58% and 52% against 20%. The other primary endpoint, fibrosis improvement, was not met (33% and 36% against 28%). The case for adding glucagon is that it acts on the liver directly rather than only through weight loss, and a short trial that clears inflammation but not yet scarring does not settle it.
PMID 41237796 ↗NCT05989711 ↗DOI 10.1016/S0140-6736(25)02114-2 ↗
#9SURPASS-3 MRI
Gastaldelli A, Cusi K, Fernández Landó L, et al. · Lancet Diabetes Endocrinol · 2022
What it measured: How much liver fat disappeared on MRI over a year
An imaging substudy inside a diabetes trial: 296 adults with a high fatty liver index, given tirzepatide or insulin degludec for 52 weeks. From a baseline near 16%, liver fat fell 8.1 percentage points on the 10 and 15 mg doses pooled against 3.4 on insulin, and visceral fat fell too. It was an early randomized sign that tirzepatide reduces liver fat, published two years before tirzepatide's biopsy trial at the top of this list.
PMID 35468325 ↗NCT03882970 ↗DOI 10.1016/S2213-8587(22)00070-5 ↗
#10GLP-1 MASH class meta-analysis
Mantovani A, Morandin R, Fiorio V, et al. · Liver Int · 2025
What it measured: Inflammation and scarring outcomes pooled across the biopsy trials
The 2025 pooling of 13 randomized trials of GLP-1 receptor agonists, led by semaglutide; four of them used biopsy. Odds of MASH resolution came out about three and a half times placebo. The important line is the split: fibrosis improvement reached significance in patients without cirrhosis, while for cirrhosis the only trial available was the one above, which showed no benefit. The boundary is consistent, but on the cirrhosis side it still rests on that single trial.
PMID 40736113 ↗DOI 10.1111/liv.70256 ↗
About this list
Obesity medicine throws up the same handful of questions over and over, and we answer them with ranked lists anchored to the papers themselves. On 2026-10-30 every citation below was put back through PubMed. Where a trial has a registry entry, the card carries that link too, alongside the PubMed one.
Browse our full index of research lists or our long-form research articles.